Alpha 2.0
Login Register
» Authors » Shengle Zhang

Shengle Zhang

Explore the profile of Shengle Zhang including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 34
Citations 397
Followers 0
Related Specialties
Pathology
Molecular Biology
Oncology
Top 10 Co-Authors
Sarabjot Pabla
Jamie Tull
Jeffrey M Conroy
Mary K Nesline
Shakti Ramkissoon
Taylor J Jensen
Kyle C Strickland
Marcia Eisenberg
Shuang Gao
Rebecca A Previs
Published In
Diagn Mol Pathol
Appl Immunohistochem Mol Morphol
J Mol Diagn
Am J Clin Pathol
PLoS One
Affiliations
Soon will be listed here.
Recent Articles
1.
Fully automated extraction of high-quality total nucleic acids from FFPE specimens for comprehensive genomic profiling of solid tumors
Amirault K, Collins M, Beker L, Mills B, Werner M, Andreas J, et al.
SLAS Technol . 2025 Feb; 31:100252. PMID: 39892788
Comprehensive Genomic Profiling (CGP) has emerged as a progressive standard of care for the understanding clinical oncology and treatment of solid tumors (Conroy, Pabla et al. 2021). By identifying actionable...
2.
A consensus-based classification workflow to determine genetically inferred ancestry from comprehensive genomic profiling of patients with solid tumors
Wallen Z, Nesline M, Pabla S, Gao S, Vanroey E, Hastings S, et al.
Brief Bioinform . 2024 Oct; 25(6). PMID: 39471413
Disparities in cancer diagnosis, treatment, and outcomes based on self-identified race and ethnicity (SIRE) are well documented, yet these variables have historically been excluded from clinical research. Without SIRE, genetic...
3.
Comprehensive Assessment of Immune Phenotype and Its Effects on Survival Outcomes in HER2-Low versus HER2-Zero Breast Cancer
Ko H, Seager R, Pabla S, Senosain M, Van Roey E, Gao S, et al.
Breast Cancer (Dove Med Press) . 2024 Aug; 16:483-495. PMID: 39192887
Background: The understanding of molecular characteristics of HER2-low breast cancer is evolving since the establishment of trastuzumab deruxtecan. Here, we explore the differences in expression patterns of immune-related genes in...
4.
Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer
Wallen Z, Ko H, Nesline M, Hastings S, Strickland K, Previs R, et al.
Front Immunol . 2024 Jul; 15:1413956. PMID: 38975340
Introduction: Younger patients with non-small cell lung cancer (NSCLC) (<50 years) represent a significant patient population with distinct clinicopathological features and enriched targetable genomic alterations compared to older patients. However,...
5.
Immunologic Factors Associated with Differential Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer
Seager R, Ko H, Pabla S, Senosain M, Kalinski P, Van Roey E, et al.
J Pers Med . 2024 May; 14(5). PMID: 38793063
KEYNOTE-522 resulted in FDA approval of the immune checkpoint inhibitor pembrolizumab in combination with neoadjuvant chemotherapy for patients with early-stage, high-risk, triple-negative breast cancer (TNBC). Unfortunately, pembrolizumab is associated with...
6.
The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer
Nesline M, Subbiah V, Previs R, Strickland K, Ko H, DePietro P, et al.
Oncol Ther . 2024 Mar; 12(2):329-343. PMID: 38502426
Introduction: Tissue-based broad molecular profiling of guideline-recommended biomarkers is advised for the therapeutic management of patients with non-small cell lung cancer (NSCLC). However, practice variation can affect whether all indicated...
7.
Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer
Seager R, Senosain M, Van Roey E, Gao S, DePietro P, Nesline M, et al.
J Transl Med . 2024 Feb; 22(1):141. PMID: 38326843
Background: Cancer-testis antigens (CTAs) are tumor antigens that are normally expressed in the testes but are aberrantly expressed in several cancers. CTA overexpression drives the metastasis and progression of lung...
8.
The spatial pattern of Scirpus mariqueter expansion and the associated mechanism of self-organization using unmanned aerial vehicles and its significance for coastal wetland restoration
Gong G, Fang S, Gao M, Zhang B, Zhang S, Li G, et al.
Environ Monit Assess . 2023 Nov; 195(12):1537. PMID: 38010577
Understanding the spatial expansion process of salt marshes and quantifying the factors driving this expansion are crucial for the management and restoration of coastal wetlands. In this study, we aimed...
9.
PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes
Nesline M, Previs R, Dy G, Deng L, Lee Y, DePietro P, et al.
Cancers (Basel) . 2023 Oct; 15(19). PMID: 37835483
Programmed cell death ligand (PD-L1) expression by immunohistochemistry (IHC) lacks sensitivity for pembrolizumab immunotherapy selection in non-small cell lung cancer (NSCLC), particularly for tumors with low expression. We retrospectively evaluated...
10.
RNA Sequencing Identifies Novel NRG1 Fusions in Solid Tumors that Lack Co-Occurring Oncogenic Drivers
Severson E, Achyut B, Nesline M, Pabla S, Previs R, Kannan G, et al.
J Mol Diagn . 2023 May; 25(7):454-466. PMID: 37164276
NRG1 gene fusions are rare, therapeutically relevant, oncogenic drivers that occur across solid tumor types. To understand the landscape of NRG1 gene fusions, 4397 solid tumor formalin-fixed, paraffin-embedded samples consecutively...